FC Receptors (Current Topics in Microbiology and Immmunology #382)

Description

Part I: Old and new FcRs

Hiromi Kubagawa, Yoshiki Kubagawa, Dewitt Jones, Tahseen H. Nasti, Mark Walter, and Kazuhito Honjo

The Old but New IgM Fc Receptor (FcμR)

F.J. Li, W.J. Won, E.J. Becker Jr., J.L. Easlick, E. Tabengwa, R. Li, M. Shakhmatov, P.D. Burrows, and R.S. Davis

Emerging Roles for FCRL Family Members in Lymphocyte Biology and Disease

Leo C. James

Intracellular antibody immunity and the cytosolic Fc receptor TRIM21

Part II: FcR signaling

Anna Niarakis, Yacine Bounab, Luca Grieco, Roman Roncagalli, J r me Garin, Bernard Malissen, Marc Da ron, Denis Thieffry

Computational modeling of the main signaling pathways involved in mast cell activation

Tarik Attout, Andres Floto and Pierre Launay

Calcium channels in FcR signaling

Marcel Kuhny, Carolin N. Zorn, and Michael Huber

Regulation of FcεRI signaling by lipid phosphatases

Part III: FcR biology

Marc Da ron

Fc Receptors as Adaptive Immunoreceptors

Jerrard M Hayes, Eoin FJ Cosgrave, Weston B Struwe, Mark Wormald, Gavin P. Davey, Roy Jefferis, Pauline M Rudd

Glycosylation and Fc Receptors

Birgitta Heyman

Antibodies as natural adjuvants

Sanae Ben Mkaddem, Ivy Christou, Elisabetta Rossato, Laureline Berthelot, Agn's Lehuen and Renato C. Monteiro

IgA, IgA receptors and their anti-inflammatory properties

Stylianos Bournazos, David J. DiLillo and Jeffrey V. Ravetch

Humanized mice to study FcγR function

Dilip K. Challa, Ramraj Velmurugan, Raimund J. Ober and E. Sally Ward

FcRn: from molecular interactions to regulation of IgG pharmacokinetics and functions.

Part IV: FcRs and disease

Xinrui Li, Andrew W Gibson and Robert P Kimberly

Human FcR polymorphism and disease.

Hanane el Bannoudi, Andreea Ioan-Facsinay and Ren E. M. Toes

Bridging auto-antibodies and arthritis; the role of Fc Receptors

P. Mark Hogarth, Jessica C. Anania, Bruce D. Wines

The FcγR of humans and non-human primates and their interaction with IgG: Implications for induction of inflammation, resistance to infection and the use of therapeutic monoclonal antibodies

Part V: FcRs and therapeutic antibodies

Ann L White, Stephen A Beers and Mark S. Cragg

FcgRIIB as a key determinant of agonistic antibody efficacy

Jantine E. Bakema and Marjolein van Egmond

Fc receptor dependent mechanisms of monoclonal antibody therapy of cancer; professionals at work

Sybille B hm, Daniela Kao and Falk Nimmerjahn

Sweet and Sour: The role of glycosylation for the anti-inflammatory activity of immunoglobulin G